CD274 and neoplasm: Secondly, NP@ESCu significantly upregulates PD-L1 expression on tumor cells which enhances tumor responsiveness to anti-PD-L1 checkpoint blockade, establishing potent synergy between cuproptosis induction and immunotherapy 51.